:
Good morning, everyone.
We're here today pursuant to Standing Order 108(2) and the motion adopted by the committee on June 3, 2008, to study the decision of Atomic Energy of Canada Limited and the government to discontinue the MAPLE reactors project and its ramifications on the supply of isotopes.
In the first hour, we have as a witness the Hon. Gary Lunn, Minister of Natural Resources. Welcome, Minister. With him is Sue Kirby, assistant deputy minister of the energy sector, and Tom Wallace, director general of the electricity resources branch. Welcome to you both as well.
Minister, go ahead with your statement, and then we'll go directly to questions following that.
Minister, I would like to say how much I and the committee appreciate you responding so quickly to our invitation, which was only made a couple of days ago. Thanks for being here.
Go ahead, please.
:
Thank you very much, Mr. Chair. It is my pleasure to be back before you. Thank you very much for the invitation. We are quite pleased to be here.
You've just introduced my two officials at the table, Sue and Tom, who work at Natural Resources Canada and do a great job.
I would like to use the time I have available this morning in my opening statement to provide the committee with some background on the MAPLE project and the challenge our government inherited.
In accepting the decision of AECL to terminate the project, this government responded in the best interests of the Canadian taxpayer, the best interests of AECL, and the best interests of the medical community. In terms of the history of this project, let me say at the outset that the MAPLE reactors have never produced a single isotope. A reactor of this type, designed solely for the production of isotopes, has never been built anywhere in the world. The MAPLE project was unproven technology.
I want to emphasize that the risks of this project were known from the very beginning. We'll get into the timeline of this project in a minute. In fact, the Liberal government of the day was warned by AECL that this was an extremely high-risk project and was advised not to proceed. Despite this advice given to the previous government, this project began in 1996, the construction for the MAPLE reactors began in 1998, and the two reactors were in essence completed in 2000 at a cost of $140 million. It's well known that the MAPLE reactors were plagued with a variety of technical and regulatory challenges almost from the very beginning. In 2000, when the reactors were completed, the technical problems began to occur.
In 2003, three years behind schedule, the issues were severe enough that AECL had to delay the start-up even further. AECL at that point called for a full investigation of the technical problems using outside experts. Experts in nuclear technology found no solution to these problems. The reactors were not able to operate, and hence they could not produce isotopes.
Finally, 12 years later, eight years behind schedule, the reactors were still not up and running, still had not produced a single isotope. Hundreds of millions of dollars have been invested in this project. The Auditor General reported--and, I will say, on numerous occasions--that this project did have difficulties, and recently she reported that it would take hundreds of millions of dollars to continue the project. Even then there was no guarantee that the technical problems could ever be resolved or that the reactors could be licensed.
Mr. Chair, on May 16 of this year, the termination of the MAPLE project was announced by AECL. After careful review of the project, including testing done as recently as April of this year, the AECL board of directors and senior managers came to the conclusion that it was not feasible to complete the commissioning and start-up of the reactors. Complete due diligence was done on this decision. The project had failed to achieve any of its goals. No definite solutions could be found, and even at the cost of hundreds of millions of dollars, there was still no proof the reactors would be able to be licensed.
It was an unacceptable risk to the taxpayer to continue with the failed project, and it was a waste of resources to keep it going. Good governance, good business, and common sense dictated that the project had to be terminated. The reasons are obvious: it would cost hundreds of millions of dollars; it had significant unresolved technical problems; and it was eight years behind schedule and did not produce one single medical isotope.
The MAPLE reactors are in stark contrast to our CANDU reactors. The proven AECL CANDU technology has been successfully brought into production in Canada and around the world, whereas the MAPLEs have not. These two technologies exist for very different purposes. CANDU reactors have been operating safely around the world, meeting their design requirements for decades. MAPLE reactors have power output of 10 megawatts versus over 1,000 megawatts for the new ACR now under development.
The CANDU is a power reactor that runs on natural uranium. The MAPLEs were designed to use small quantities of highly enriched targets to produce isotopes that could be further processed at facilities at Chalk River and in Ottawa. In short, people who attempt to compare the MAPLE and CANDU reactors are comparing apples to oranges, as any nuclear professional will testify.
AECL has a long and well-proven track record in designing and building power reactors. CANDU 6 reactors are generating electricity in Canada, Korea, Romania, China, and Argentina. In fact, just recently I came back from Korea and China and had an opportunity to visit the reactors in China. These were the most efficient reactors running in the Chinese fleet. In Korea they have 20 nuclear reactors, and of the 20 nuclear reactors, AECL reactors are running one, two, three, and five in efficiency and performance. They are very well received.
As for the implications of the decision to terminate the MAPLE reactors, I will be very clear. The termination of the MAPLE project will have no impact whatsoever on the production of medical isotopes. The MAPLE reactors have never produced an isotope.
Isotopes will continue to be produced by the NRU reactor, which is licensed until 2011. The NRU is performing better and more safely than at any time in its operational history. I have asked AECL to pursue an extension of the NRU licence beyond that date.
Our government will work closely with AECL and MDS Nordion to pursue a life extension of the NRU to ensure that the medical community and Canadians get the supply of isotopes they need. We are also prepared to work with the international community to facilitate international supplies if the NRU needs to be shut down for periods of time in order its secure its life extension.
Over the long term, we will work with the private sector to develop solutions to bring on new sources of isotope supply. Some of the private sector solutions could be in Canada and others outside the country.
While research reactors operated by governments and universities could play a role, we expect that private sector enterprises will determine the shape of the industry. This is as it should be for isotopes and for the supply of other drugs and medical technology.
In fact, it is likely the termination of the MAPLE project will encourage additional investments to develop new sources of supply now that industry knows for certain that the project will not be completed and that there's a market opportunity. AECL and its employees are now able to concentrate on the company's core business line, the design and construction of CANDU power reactors for use in Canada and in other countries. I am assured by AECL that the direct impact on employees will be minimal.
Winding down the project and the safe shutdown of the reactors themselves will occupy many of the existing staff for at least several months. After that time, AECL expects there will be significant opportunities to re-deploy staff at both its Chalk River and Sheridan Park operations. It is also well understood that the global nuclear industry is expanding, and therefore the demand for people with these types of skills will continue to grow. In short, there are going to be more jobs than there will be people to fill them in this industry in the future.
The MAPLE reactors were born of litigation and have been the subject of commercial disputes throughout their life. AECL and MDS Nordion are now reconsidering their business relationship, as may be expected. In these circumstances, I am not at liberty, nor would it be appropriate for me, to comment on the business relationship between these two companies, nor to entertain hypotheses on how that may develop.
I understand that the committee has agreed to ask AECL and MDS Nordion to testify as well, and I imagine they will be under similar constraints. I would therefore appreciate the committee's forbearance in recognizing that I am not in a position to discuss matters that are confidential in a commercial sense.
I'd like to thank your for inviting me, and I would be pleased to take any of the members' questions. Thank you.
:
Thank you, Mr. Chairman.
Welcome, Minister. You are here for the second time in a fairly short period. I would like to remind you that, during your last visit, we asked your department to provide certain documents. We have not yet received them, however. That means either that your visits are too close together, or that your department people are too busy. I will let you draw your own conclusions. We are eager to have the documents.
Minister, the decision to terminate the MAPLE project was made on May 16. In February, I was present at the Canadian Nuclear Association annual seminar. In the hallways, I was already being told that the MAPLE project would never see the light of day. Industry people as well as the people I spoke to told me that quite frankly. It seemed to be a fact. I think the industry was waiting for AECL's decision. My reaction as a citizen and as a member new to nuclear issues was to wonder why it had taken so long, why millions of dollars of Quebec and Canadian taxpayers' money had been sunk into a project that no one, it seemed, actually expected to see implemented.
You also say that nuclear energy is clean energy. But in my view it is also very expensive energy. In your comments, you say that hundreds of millions of taxpayers' and private sector dollars were sunk into the project and spent needlessly.
I would like to know the exact amount that taxpayers and the private sector were obliged to invest in this project, which will never see the light of day. This is a very short and succinct question. Do you have the figures, Minister?
:
Thank you, Minister. I'm satisfied with your answer.
You seem very optimistic, even candid, about the future of medical isotope production. You tell us that the permit is valid until 2011, and that the private sector and AECL are already working on alternative solutions. As you know, the reactor is 50 years old. Even if an alternative solution is found, I don't know whether the life of a reactor like this can be extended for many more years. In my view, it already seems to have reached an unacceptable limit.
The Canadian Society of Nuclear Medicine does not share your optimism. On May 21, the society issued a press release in which it expressed concerns about isotope supplies. It stated that it was aware of no realistic contingency plan for the medium and long term, and believes there is a lack of planning that is jeopardizing medical diagnostic services. That is the position of the Canadian Society of Nuclear Medicine.
The experts—those who use the isotopes—are not convinced your optimism is well placed, and have no information on what may really happen in the future.
At this moment, Minister, are there any plans on the development of the reactor's safety beyond 2011 that we could look at? What sort of planning is th ere? Until now, I have not been very impressed by the planning performance of AECL. AECL failed in its duty in administering and managing the medical isotope crisis.
Can you tell us specifically what is on the table, and what the short term plan is? Everyone knows that a reactor is not built in three years, and that solutions must frequently be implemented over the long term. Since the medical community is concerned, I would like you to tell us clearly what the plan is for action beyond 2011.
With respect to this decision, obviously to terminate the MAPLE project...there were no isotopes being produced, so this decision does not impact on the production of isotopes. As far as the future goes--and I hear your comments loud and clear--let me say this. The NRU, as I've said, is a marvellous piece of technology. You're correct, it's 50 years old, but in fairness, it's had a number of upgrades done recently to meet the current licensing conditions. The reactor is operating as efficiently and as safely as it ever has before in its entire history.
When I speak with the experts--and you're going to get an opportunity to talk to AECL, I understand, after me, and you can question them--they are now working with the CNSC. They've engaged in those discussions about post-2011, and I have no reason to believe they will not be able to license that. They may require some further upgrades. I don't know that, but I can tell you this. The government is committed to putting the resources that are required to ensure that this can be done.
Those discussions are ongoing, and the fact that we've made this decision on the MAPLE project allows us now to ask, what is going to be out there in the long term? Already people from the private sector have approached me about different possibilities. Now, they are just literally discussions coming into my office, but from pretty serious people. I'm not going to get into those details. I believe that would be in their interest, not mine, to start speculating about what may or may not come out. But the fact is that we've made this decision. We can now focus on other alternatives as well.
But the NRU is doing an amazing job right now. As I said earlier, it's an amazing piece of technology. I have every reason to believe it will continue. I hear the concerns of the medical community. That is why we made the decision we did. It was long overdue. This project should never have begun. They were warned. The Auditor General, on numerous occasions, warned of the problems with this project.
This is well over a decade. I think we're acting very prudently, very responsibly. They're nuclear decisions. You just don't make them overnight. You have to do your due diligence. You have to do your homework, and that is exactly what we have done.
Thank you, Minister and folks, for coming here today. I appreciate it.
In one of his questions, Mr. Alghabra talked about your November 1 memo in which you were provided with three options. I'm comforted to see that at least the management oversight gave you options to look at it, even though there's a recommendation. You made the comment that we might be looking a number of years out before this could ever be done.
The Auditor General, in her remarks of September 5, 2007, on the special examination, said that the estimate at that point in time was for probably around $130 million to complete the two reactors, one of which would be done in 2008 and one in 2009.
Given that consideration, what kinds of estimates did you foresee that it would have taken—just a ball park range—to finish these if you went ahead?
:
You can read between the lines, and you can read what Mr. Dhaliwal has said. I'll let the media and the public judge for themselves what he was saying.
The reality is that under the previous government, which began the project in 1996, up until they left office in 2005--despite numerous warnings from the Auditor General--the flags were there. This was a political decision. They elected not to make that decision. For whatever reason, they chose to ignore this and not make the decision.
I'll say that we've been in office for two years. Listen, when you're making nuclear decisions, there's a lot of work to be done. There's a lot of due diligence. You know, you don't come into office and make a decision six months later. These are significant decisions. I think we've acted appropriately. Should a decision have been made a long time ago? I think these tests and this work could have been done a long time ago, and it would have saved a significant amount of money. The fact is that they weren't, but our government is prepared to take leadership and make the decisions we have made to terminate this project. We believe it's in the best interest of the taxpayer, AECL, and the medical community.
I'll just add something. Why is it in the best interest of AECL? As you know, we are having a nuclear renaissance. And I want to say this about AECL. They are in the business of building power reactors. Their reactors operate as some of the most efficient reactors anywhere in the world. Their performance on the international stage has been to build nuclear reactors on time and under budget. The men and women who work at AECL--the nuclear engineers, the nuclear scientists--are some of the best in the world. I think this decision also allows them to focus on what they do best, and that's building nuclear reactors to produce electricity.
The reality is that the world is changing. We're seeing opportunities both at home and abroad. That's another reason this decision is so important. They warned previous governments about the risk of this project. I think it's safe to say that this project should never have started. But we can allow them to get back to what they do well. That's an important part of this decision.
:
That's why we released it in four months. We released it well within the normal timeframes to do the review and release that report.
I will also say that the period covered under that Auditor General's report largely was during the previous government. Her report covered a period, the majority of which was actually reporting on the record of the previous Liberal government. This report was completed about a year after we took office, and there was about six months, I believe, if my memory serves me correctly, of time covered by our government. But prior to that it was the previous government.
Instead of getting into a discussion of whether I released it within three months or four months or two months...we absolutely released it. But more important is what's in the report, which is that the major deficiencies were never corrected. She identified the same problems in her 2002 report, which the previous government ignored.
I think our performance with respect to the MAPLE decision indicates we did the right thing. We did it in the right timeframe. We did our due diligence. We did the tests to ensure that we adequately protected the investment by the taxpayer. And once we had done all of that work, we made the correct decision.
I think the Auditor General, in a subsequent report, will applaud our decision and the steps we took to do our due diligence.
:
First of all, I think that's a legitimate question. It's a concern for me and it's a concern for AECL. Even though they identified the MAPLE as a high-risk project and advised against it, they are concerned about that. But I will say emphatically that the MAPLE technology is completely separate. It's completely different from the ACR technology, which they're doing. And to their credit, the ACR technology, the advanced CANDU reactor, is built on the CANDU 6 platform. About 80% of the parts, or even more, in the CANDU 6 are interchangeable with the ACR. So that's the platform.
Look at their record. That's what I say. Look at the record. I was in Argentina, and I went inside the reactor. They have awards for the most efficient reactor in the world.
In China there is Qinshan 1 and 2. I was there a few weeks ago. Again, if you listen to the engineers there, of all the Chinese reactors in the entire Chinese fleet, the two CANDUs have the shortest construction time, are the most efficient reactors, were on time and under budget, are the least expensive per unit of energy, and use the least amount of uranium per unit of energy produced. They're marvellous pieces of technology.
It's the same thing in Korea. They have 20 reactors. Ours are four of the top five, and soon, I'm told, will be four of the top four.
Let me just finish.
The record is very strong.
As far as the England bid in the U.K is concerned--you raised this, so I just want to touch on this if I can--the cost of just doing the bid is $25 million to $30 million. They have opportunities here at home. They want to do what they do, and they want to do it well. So they had to make a strategic decision.
We have a lot of work here in Canada. We have New Brunswick talking to us. We have Ontario. And we're hearing interest in Alberta. Let's focus our priorities on Canada right now to get the ARC platform and get it producing electricity. I actually think it's going to be award winning, from everything I read.
So I think they made the right decision, a strategic decision, to not continue the U.K. bid process. That's not to mention the cost.
:
There's a CANDU 6 or 6E, the enhanced CANDU 6, which produces 740 megawatts. That's probably around 726 or 740. The ACR-1000 actually produces 1,140 megawatts of electricity. I'm not even sure how they came up with these numbers.
As for its problems, the CANDU 6 is a tried and proven technology that's operating well. It's operating in Canada and operating around the world.
The ACR has never been built, so it is a new technology. It's built on the CANDU 6 platform. It's about 80%.... You know, the parts are interchangeable, but it's the next generation. It's called Generation III technology. There are no Generation III reactors operational anywhere in the world. There are a few under construction, and they are not without their challenges.
Listen, we have some of the best people at AECL. I have been out to meet the nuclear scientists and engineers at Chalk River and at Sheridan Park. I absolutely believe that our greatest asset is our people at AECL, and I have a lot of confidence in them. I do. And I think we have an ability to create a Canadian champion.
That's why our government has put the resources into it. In the budget of this year we put $300 million into AECL. The reality is that I think nuclear is going to play a much increased role in electricity production. It's greenhouse-gas-emission-free. It's pollution-free. It's not without its challenges, but it will be part of our energy mix in the future. We're seeing that Ontario has launched a bid process for two new reactors, something we haven't built for decades in Canada.
:
Yes, I do, Mr. Chairman. Thank you very much.
[Translation]
Thank you, Mr. Chairman and members of the Standing Committee on Natural Resources.
I am here with our vice-president and general counsel, Allan Hawryluk.
[English]
Ladies and gentlemen, I joined AECL in January, on the same day that Glenna Carr was appointed chair of our board. We joined a company with a proud 56-year history of being the stewards of Canada's nuclear platform. We joined a company with a tremendous future as we stand on the cusp of a global nuclear renaissance. I joined the company from outside the nuclear industry, but with experience in both the transportation and technology sectors. In fact, as a former officer of the Canadian Pacific Railway, I feel rather comfortable in the railway committee room today.
AECL has a dual mandate. The first is to be a successful architect and developer of commercial nuclear power reactors around the world, something we do very well and in which we have a tremendous future. The committee is well aware of the strong business and environmental case that exists for nuclear power, and we are determined to be a major player in the global market with our CANDU brand.
The second part of our mandate is to be the platform for Canada's nuclear science and technology. AECL's major research and development efforts take place at the Chalk River laboratories. Our scientists and engineers perform research and product development to support and advance CANDU's nuclear reactor technology. The facility has world-class expertise in physics, metallurgy, chemistry, biology, and engineering. AECL's research and development infrastructure there enables the production of medical isotopes, and we supply those through an exclusive business arrangement with MDS Nordion.
The special examination report of the Auditor General, released in January, highlighted three deficiencies, as they termed it, in the company that needed to be addressed, one being the resolution of issues surrounding the dedicated isotope facility. That report succinctly summarized some of the challenges this project faced. So, as would any incoming business executive, I wanted to undertake a broad-gauge review of the business and the issues.
The first and largest is the technical challenge. The physics of the MAPLE reactors were presenting certain mysteries, most particularly in regard to the PCR coefficient, the power coefficient of reactivity. We made every effort to solve these mysteries, but the answers were eluding the best minds in nuclear science. Furthermore, the costs and timeframes for commissioning and licensing the MAPLEs were increasing in the absence of a technical solution.
A second issue related to the uncertainty of the marketplace. The market for isotopes produced by AECL was changing, and it was clear that new sources of supply were coming onstream around the world. It was also clear that the worldwide movement towards producing isotopes from low-enriched uranium targets, a movement born out of concern for nuclear proliferation, could leave a facility designed on the basis of highly enriched uranium targets—the MAPLEs—obsolete in a matter of a few years, even prior to completion.
Thirdly, we looked at our obligations and options with regard to our contract with MDS Nordion, in particular a deadline to bring MAPLE 1 into production by October of this year. We were very aware of the concerns of the health care community for their patients. It was clear that swift resolution was key and that if the MAPLEs couldn't be the solution, we needed to be mobilizing quickly with another workable plan.
Another consideration, of course, in all of this was for the hundreds of dedicated AECL employees who have devoted the past 12 years to this project. Taken together, it became clear to AECL management and was confirmed with our board that meeting the October 2008 deadline for commissioning MAPLE 1 was improbable.
Throughout the process, we continued our work on solving the technical challenges leading up to a milestone test, as the minister mentioned, on the reactor in mid-April. Once that test was conducted and failed to resolve the PCR issue, there was a tipping point for our decision. The factors we considered—the significant cost, the technical risk, the timeframe, as well as our contractual obligations—were placed in the context of a broad look at the marketplace, and we came to the conclusion that the case for continuing the MAPLE project could not be supported.
This is what got us to where we are today.
Discontinuing the dedicated isotope facility project does not affect the short- or medium-term supply of isotopes. We will continue to supply and continue to produce from the NRU, and our focus now is on making sure this reactor is as reliable as it can possibly be until the end of its current licence period, and taking the steps necessary to extend that licence beyond 2011.
[Translation]
It was a difficult, but necessary, decision.
[English]
It was made based on facts and the best available evidence and advice. It was made by looking forward, not back, and made in good faith and with the best interests of the taxpayers of Canada in mind.
Mr. Chairman, that concludes my remarks.
[Translation]
I would be pleased to answer questions from committee members.
:
Maybe before I do that I should just say a good thank you to Mr. Wallace for handing off the technical explanations to me, drawing deeply on my five months of experience in the industry.
With respect to the ACR you mentioned—and I'm not talking based on first-hand knowledge, but more recounting what my colleagues have briefed me on—the machine that was being evaluated at that time was the ACR-700, as opposed to the ACR-1000. So it was indeed an earlier generation of the current product.
At that time, the NRC said there were no fundamental barriers to the licensability of the machine, but it was clear from a marketing point of view that we needed to make changes that would result in a power reactor, the ACR-1000, that had a negative PCR design. That is in fact the case today; the ACR-1000 is indeed designed to that basis.
The other thing I should point out, though, is that although these measures are cousins of each other, they are not the same. So the PCR coefficient and the way it's measured and applied and interpreted, as it relates to the MAPLE reactor, is not the same, and you can't draw a direct conclusion between one and the other.
:
I am certainly happy to talk about that, because it is important.
The first thing is that we have implemented a communications protocol that is clearly understood at all levels within our organization and various aspects of the supply chain, such that in the event that there is even the risk of a shortage of delivery, all of the appropriate communications take place and the ability to start to plan alternative sources kicks in. You know well that these isotopes have a short half-life, so there's not a lot of time.
We also understand that our colleagues at Health Canada are actively examining ways to improve the communications and coordination across the supply chain and the reach into the medical community so that there's a coordinated response in the event of an unplanned outage.
Certainly our goal, as you can imagine, is that we not have any outage caused by the same factors that occurred last November and December. Equally, in relation to the technical performance of the reactor today, we have every evidence to suggest that it's been operating at the highest levels of reliability and continues to do that.
As we move closer to the end of the current licensing period, there will likely be some periods when we will need to shut the reactor down for a longer period of time than is currently the case. It will be measured in weeks rather than days. Our view today is that with proper planning and coordination, we will be able to successfully coordinate and manage a reactor outage of, say, three weeks' duration, such that we will be able to undertake any work that needs to be done. It is certainly in our planning frame to be able to deal with that kind of eventuality in a planned way.